Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV observational database

Jialun Zhou, N. I. Paton, R. Ditangco, Y. M.A. Chen, A. Kamarulzaman, N. Kumarasamy, C. K.C. Lee, P. C.K. Li, F. Yuliana, P. Phanuphak, S. Pujari, A. Vibhagool, F. Zhang, J. Chuah, K. R. Frost, D. A. Cooper, M. G. Law, C. V. Mean, V. Saphonn, F. ZhangH. Zhao, N. Han, P. Li, M. P. Lee, N. Kumarasamy, J. A. Cecelia, K. Joshi, F. Yuliana, S. Oka, M. Honda, J. Pang, R. Capistrano, W. W.Y. Wong, R. Chang, P. L. Lim, C. K.C. Lee, S. M. Thitsar, M. Khongphattanayothing, S. Kiertiburanakul, W. Kiatatchasai, T. Sirianthana

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: The antiretroviral treatment (ART) combination of stavudine, lamivudine and nevirapine (d4T/3TC/NVP) is the most frequently used initial regimen in many Asian countries. There are few data on the outcome of this treatment in clinic cohorts in this region. Methods: We selected patients from the TREAT Asia HIV Observational Database (TAHOD) who started their first ART regimen with d4T/3TC/NVP. Treatment change was defined as cessation of therapy or the addition or change of one or more drugs. Clinical failure was defined as diagnosis with an AIDS-defining illness, or death while on d4T/3TC/NVP treatment. Results: The rate of treatment change among TAHOD patients starting d4T/3TC/NVP as their first antiretroviral treatment was 22.3 per 100 person-years, with lower baseline haemoglobin (i.e. anaemia) associated with slower rate of treatment change. The rate of clinical failure while on d4T/3TC/NVP treatment was 7.3 per 100 person-years, with baseline CD4 cell count significantly associated with clinical failure. After d4T/3TC/ NVP was stopped, nearly 40% of patients did not restart any treatment and, of those who changed to other treatment, the majority changed to zidovudine (ZDV)/3TC/NVP and less than 3% of patients changed to a protease inhibitor (PI)-containing regimen. The rates of disease progression on the second-line regimen were similar to those on the first-line regimen. Conclusion: These real-life data provide an insight into clinical practice in Asia and the Pacific region. d4T/3TC/NVP is maintained longer than other first-line regimens and change is mainly as a result of adverse effects rather than clinical failure. There is a need to develop affordable second-line antiretroviral treatment options for patients with HIV infection in developing countries.

Original languageEnglish
Pages (from-to)8-16
Number of pages9
JournalHIV Medicine
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 1 2007
Externally publishedYes

Fingerprint

Lamivudine
HIV
Databases
Therapeutics
stavudine, lamivudine, nevirapine drug combination
Zidovudine
CD4 Lymphocyte Count
Protease Inhibitors
Developing Countries
HIV Infections
Disease Progression
Anemia
Acquired Immunodeficiency Syndrome
Hemoglobins

Keywords

  • Adverse effects
  • Antiretroviral treatment
  • Asia-Pacific region
  • Stavudine/lamivudine/nevirapine
  • Treatment change

ASJC Scopus subject areas

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV observational database. / Zhou, Jialun; Paton, N. I.; Ditangco, R.; Chen, Y. M.A.; Kamarulzaman, A.; Kumarasamy, N.; Lee, C. K.C.; Li, P. C.K.; Yuliana, F.; Phanuphak, P.; Pujari, S.; Vibhagool, A.; Zhang, F.; Chuah, J.; Frost, K. R.; Cooper, D. A.; Law, M. G.; Mean, C. V.; Saphonn, V.; Zhang, F.; Zhao, H.; Han, N.; Li, P.; Lee, M. P.; Kumarasamy, N.; Cecelia, J. A.; Joshi, K.; Yuliana, F.; Oka, S.; Honda, M.; Pang, J.; Capistrano, R.; Wong, W. W.Y.; Chang, R.; Lim, P. L.; Lee, C. K.C.; Thitsar, S. M.; Khongphattanayothing, M.; Kiertiburanakul, S.; Kiatatchasai, W.; Sirianthana, T.

In: HIV Medicine, Vol. 8, No. 1, 01.01.2007, p. 8-16.

Research output: Contribution to journalArticle

Zhou, J, Paton, NI, Ditangco, R, Chen, YMA, Kamarulzaman, A, Kumarasamy, N, Lee, CKC, Li, PCK, Yuliana, F, Phanuphak, P, Pujari, S, Vibhagool, A, Zhang, F, Chuah, J, Frost, KR, Cooper, DA, Law, MG, Mean, CV, Saphonn, V, Zhang, F, Zhao, H, Han, N, Li, P, Lee, MP, Kumarasamy, N, Cecelia, JA, Joshi, K, Yuliana, F, Oka, S, Honda, M, Pang, J, Capistrano, R, Wong, WWY, Chang, R, Lim, PL, Lee, CKC, Thitsar, SM, Khongphattanayothing, M, Kiertiburanakul, S, Kiatatchasai, W & Sirianthana, T 2007, 'Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV observational database', HIV Medicine, vol. 8, no. 1, pp. 8-16. https://doi.org/10.1111/j.1468-1293.2007.00417.x
Zhou, Jialun ; Paton, N. I. ; Ditangco, R. ; Chen, Y. M.A. ; Kamarulzaman, A. ; Kumarasamy, N. ; Lee, C. K.C. ; Li, P. C.K. ; Yuliana, F. ; Phanuphak, P. ; Pujari, S. ; Vibhagool, A. ; Zhang, F. ; Chuah, J. ; Frost, K. R. ; Cooper, D. A. ; Law, M. G. ; Mean, C. V. ; Saphonn, V. ; Zhang, F. ; Zhao, H. ; Han, N. ; Li, P. ; Lee, M. P. ; Kumarasamy, N. ; Cecelia, J. A. ; Joshi, K. ; Yuliana, F. ; Oka, S. ; Honda, M. ; Pang, J. ; Capistrano, R. ; Wong, W. W.Y. ; Chang, R. ; Lim, P. L. ; Lee, C. K.C. ; Thitsar, S. M. ; Khongphattanayothing, M. ; Kiertiburanakul, S. ; Kiatatchasai, W. ; Sirianthana, T. / Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV observational database. In: HIV Medicine. 2007 ; Vol. 8, No. 1. pp. 8-16.
@article{6928243cfc6a4fcea9cf701d8600b701,
title = "Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV observational database",
abstract = "Background: The antiretroviral treatment (ART) combination of stavudine, lamivudine and nevirapine (d4T/3TC/NVP) is the most frequently used initial regimen in many Asian countries. There are few data on the outcome of this treatment in clinic cohorts in this region. Methods: We selected patients from the TREAT Asia HIV Observational Database (TAHOD) who started their first ART regimen with d4T/3TC/NVP. Treatment change was defined as cessation of therapy or the addition or change of one or more drugs. Clinical failure was defined as diagnosis with an AIDS-defining illness, or death while on d4T/3TC/NVP treatment. Results: The rate of treatment change among TAHOD patients starting d4T/3TC/NVP as their first antiretroviral treatment was 22.3 per 100 person-years, with lower baseline haemoglobin (i.e. anaemia) associated with slower rate of treatment change. The rate of clinical failure while on d4T/3TC/NVP treatment was 7.3 per 100 person-years, with baseline CD4 cell count significantly associated with clinical failure. After d4T/3TC/ NVP was stopped, nearly 40{\%} of patients did not restart any treatment and, of those who changed to other treatment, the majority changed to zidovudine (ZDV)/3TC/NVP and less than 3{\%} of patients changed to a protease inhibitor (PI)-containing regimen. The rates of disease progression on the second-line regimen were similar to those on the first-line regimen. Conclusion: These real-life data provide an insight into clinical practice in Asia and the Pacific region. d4T/3TC/NVP is maintained longer than other first-line regimens and change is mainly as a result of adverse effects rather than clinical failure. There is a need to develop affordable second-line antiretroviral treatment options for patients with HIV infection in developing countries.",
keywords = "Adverse effects, Antiretroviral treatment, Asia-Pacific region, Stavudine/lamivudine/nevirapine, Treatment change",
author = "Jialun Zhou and Paton, {N. I.} and R. Ditangco and Chen, {Y. M.A.} and A. Kamarulzaman and N. Kumarasamy and Lee, {C. K.C.} and Li, {P. C.K.} and F. Yuliana and P. Phanuphak and S. Pujari and A. Vibhagool and F. Zhang and J. Chuah and Frost, {K. R.} and Cooper, {D. A.} and Law, {M. G.} and Mean, {C. V.} and V. Saphonn and F. Zhang and H. Zhao and N. Han and P. Li and Lee, {M. P.} and N. Kumarasamy and Cecelia, {J. A.} and K. Joshi and F. Yuliana and S. Oka and M. Honda and J. Pang and R. Capistrano and Wong, {W. W.Y.} and R. Chang and Lim, {P. L.} and Lee, {C. K.C.} and Thitsar, {S. M.} and M. Khongphattanayothing and S. Kiertiburanakul and W. Kiatatchasai and T. Sirianthana",
year = "2007",
month = "1",
day = "1",
doi = "10.1111/j.1468-1293.2007.00417.x",
language = "English",
volume = "8",
pages = "8--16",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV observational database

AU - Zhou, Jialun

AU - Paton, N. I.

AU - Ditangco, R.

AU - Chen, Y. M.A.

AU - Kamarulzaman, A.

AU - Kumarasamy, N.

AU - Lee, C. K.C.

AU - Li, P. C.K.

AU - Yuliana, F.

AU - Phanuphak, P.

AU - Pujari, S.

AU - Vibhagool, A.

AU - Zhang, F.

AU - Chuah, J.

AU - Frost, K. R.

AU - Cooper, D. A.

AU - Law, M. G.

AU - Mean, C. V.

AU - Saphonn, V.

AU - Zhang, F.

AU - Zhao, H.

AU - Han, N.

AU - Li, P.

AU - Lee, M. P.

AU - Kumarasamy, N.

AU - Cecelia, J. A.

AU - Joshi, K.

AU - Yuliana, F.

AU - Oka, S.

AU - Honda, M.

AU - Pang, J.

AU - Capistrano, R.

AU - Wong, W. W.Y.

AU - Chang, R.

AU - Lim, P. L.

AU - Lee, C. K.C.

AU - Thitsar, S. M.

AU - Khongphattanayothing, M.

AU - Kiertiburanakul, S.

AU - Kiatatchasai, W.

AU - Sirianthana, T.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background: The antiretroviral treatment (ART) combination of stavudine, lamivudine and nevirapine (d4T/3TC/NVP) is the most frequently used initial regimen in many Asian countries. There are few data on the outcome of this treatment in clinic cohorts in this region. Methods: We selected patients from the TREAT Asia HIV Observational Database (TAHOD) who started their first ART regimen with d4T/3TC/NVP. Treatment change was defined as cessation of therapy or the addition or change of one or more drugs. Clinical failure was defined as diagnosis with an AIDS-defining illness, or death while on d4T/3TC/NVP treatment. Results: The rate of treatment change among TAHOD patients starting d4T/3TC/NVP as their first antiretroviral treatment was 22.3 per 100 person-years, with lower baseline haemoglobin (i.e. anaemia) associated with slower rate of treatment change. The rate of clinical failure while on d4T/3TC/NVP treatment was 7.3 per 100 person-years, with baseline CD4 cell count significantly associated with clinical failure. After d4T/3TC/ NVP was stopped, nearly 40% of patients did not restart any treatment and, of those who changed to other treatment, the majority changed to zidovudine (ZDV)/3TC/NVP and less than 3% of patients changed to a protease inhibitor (PI)-containing regimen. The rates of disease progression on the second-line regimen were similar to those on the first-line regimen. Conclusion: These real-life data provide an insight into clinical practice in Asia and the Pacific region. d4T/3TC/NVP is maintained longer than other first-line regimens and change is mainly as a result of adverse effects rather than clinical failure. There is a need to develop affordable second-line antiretroviral treatment options for patients with HIV infection in developing countries.

AB - Background: The antiretroviral treatment (ART) combination of stavudine, lamivudine and nevirapine (d4T/3TC/NVP) is the most frequently used initial regimen in many Asian countries. There are few data on the outcome of this treatment in clinic cohorts in this region. Methods: We selected patients from the TREAT Asia HIV Observational Database (TAHOD) who started their first ART regimen with d4T/3TC/NVP. Treatment change was defined as cessation of therapy or the addition or change of one or more drugs. Clinical failure was defined as diagnosis with an AIDS-defining illness, or death while on d4T/3TC/NVP treatment. Results: The rate of treatment change among TAHOD patients starting d4T/3TC/NVP as their first antiretroviral treatment was 22.3 per 100 person-years, with lower baseline haemoglobin (i.e. anaemia) associated with slower rate of treatment change. The rate of clinical failure while on d4T/3TC/NVP treatment was 7.3 per 100 person-years, with baseline CD4 cell count significantly associated with clinical failure. After d4T/3TC/ NVP was stopped, nearly 40% of patients did not restart any treatment and, of those who changed to other treatment, the majority changed to zidovudine (ZDV)/3TC/NVP and less than 3% of patients changed to a protease inhibitor (PI)-containing regimen. The rates of disease progression on the second-line regimen were similar to those on the first-line regimen. Conclusion: These real-life data provide an insight into clinical practice in Asia and the Pacific region. d4T/3TC/NVP is maintained longer than other first-line regimens and change is mainly as a result of adverse effects rather than clinical failure. There is a need to develop affordable second-line antiretroviral treatment options for patients with HIV infection in developing countries.

KW - Adverse effects

KW - Antiretroviral treatment

KW - Asia-Pacific region

KW - Stavudine/lamivudine/nevirapine

KW - Treatment change

UR - http://www.scopus.com/inward/record.url?scp=33846270355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846270355&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2007.00417.x

DO - 10.1111/j.1468-1293.2007.00417.x

M3 - Article

C2 - 17305926

AN - SCOPUS:33846270355

VL - 8

SP - 8

EP - 16

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 1

ER -